8229 Boone Boulevard, Suite 802
Vienna, VA 22182
Phone: (703) 506-9460
CEL-SCI Corporation (“CEL-SCI” or “the Company”) is a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The Company is targeting novel therapy candidates that activate and utilize the body’s own immune system against disease. CEL-SCI is developing products based on two technologies: (1) Multikine® (Leukocyte Interleukin, Injection), an immunotherapy nearing the end of a global pivotal Phase 3 trial as a first-line treatment for head and neck cancer; and (2) LEAPS™ (Ligand Epitope Antigen Presentation System), an immunotherapy vaccine technology platform. The goal of Multikine® is to modulate the body’s immune system to create a two-pronged mechanism of action: eliciting the direct killing of tumor cells and micrometastasis, limiting the possibility of recurrence, while generating a sustainable anti-tumor response, and rendering tumor cells more susceptible to subsequent radiation and chemotherapy treatments. Multikine® is being developed for neoadjuvant administration and could become an integral first-line component of the standard of care (SOC) regimen for advanced primary (previously untreated) head and neck cancers. As a neoadjuvant, Multikine® can stimulate the immune system before it is weakened by the toxic cancer therapies, improving its long-term therapeutic effect. The LEAPS™ platform is designed to stimulate the immune system to fight bacterial, viral, and parasitic infections more effectively, as well as autoimmune conditions and cancer. LEAPS™ can be designed to produce a specific natural immune response required for the desired therapeutic effect, depending on the type of LEAPS™ construct used.
* The Corporate Snapshot was last updated on June 3, 2020.